Prognostic Nomogram and Therapeutic Option of Cancer-Specific Death in the Patients with Metachronous Second Primary Lung Cancer

Table 2

Competing risk analyses of cancer cause death among patients with metachronous second primary lung cancer.

	Univariate analysis		Multivariate analysis
	SHR		SHR
Age
<65 years	Ref		Ref
≥65 years	1.26 (1.01, 1.59)	0.049	1.32 (1.02, 1.72)	0.036
Sex
Female	Ref		Ref
Male	1.38 (1.16, 1.64)	<0.001	1.26 (1.03, 1.54)	0.024
Marital status
Unmarried	Ref		Ref
Married	0.77 (0.65, 0.92)	0.004	0.79 (0.65, 0.96)	0.021
Race
White	Ref
Black	1.29 (0.80, 2.08)	0.293
Other	1.13(0.73,1.75)	0.574
Laterality (SPLC)
Left	Ref
Right	1.01 (0.85, 1.20)	0.92
Primary site(SPLC)
Main	Ref		Ref
Upper	0.36 (0.23, 0.56)	<0.001	0.85 (0.54,1.35)	0.5
Middle	0.26 (0.15, 0.44)	<0.001	0.53 (0.29, 0.96)	0.036
Low	0.32 (0.20, 0.50)	<0.001	0.75 (0.46,1.21)	0.233
Histology (SPLC)
Small cell carcinoma	Ref		Ref
Large cell carcinoma	0.39 (0.24, 0.65)	<0.001	0.85 (0.49, 1.45)	0.542
Squamous cell carcinoma	0.38 (0.29, 0.51)	<0.001	0.66 (0.47, 0.92)	0.015
Adenocarcinoma	0.24 (0.19, 0.31)	<0.001	0.49 (0.35, 0.67)	0.001
Other	0.28 (0.19, 0.42)	<0.001	0.48 (0.30, 0.79)	0.004
Tumor size(SPLC)
≤2 cm	Ref		Ref
>2 cm	2.23 (1.87, 2.66)	<0.001	1.39(1.12,1.73)	0.003
AJCC N, 6th ed (SPLC)
N0	Ref		Ref
N1	2.77 (1.94, 3.95)	<0.001	1.68 (1.06, 2.65)	0.027
N2	3.87 (3.07, 4.89)	<0.001	1.75 (1.19, 2.87)	0.004
N3	5.13 (3.73,7.91)	<0.001	1.70 (1.05, 2.74)	0.029
AJCC T, 6th ed(SPLC)
T1	Ref		Ref
T2	1.88 (1.54, 2.31)	<0.001	1.44 (1.17, 1.76)	<0.001
T3	2.68 (1.69, 4.26)	<0.001	1.36 (0.90, 2.36)	0.142
T4	1.96 (1.55, 2.49)	<0.001	1.07 (0.82, 1.41)	0.60
Tumor stage (SPLC)
I	Ref		Ref
II	1.71(1.13, 2.99)	0.011	1.34 (0.68, 2.62)	0.399
III	2.46 (1.98, 3.06)	<0.001	1.81 (1.03, 3.19)	0.039
IV	4.06 (3.18, 5.19)	<0.001	2.17 (1.23, 4.18)	0.020
SEER combined summary stage (SPLC)
Localized	Ref		Ref
Regional	1.71 (1.39, 2.10)	<0.001	0.75 (0.47, 1.18)	0.216
Distant	3.85 (3.07, 4.83)	<0.001	0.96 (0.51, 1.78)	0.887
Chemotherapy (SPLC)
No/unknown	Ref		Ref
Yes	2.23 (1.87, 2.67)	<0.001	0.85 (0.65, 1.13)	0.24
Radiation/surgery (SPLC)
No	Ref		Ref
Surgery alone	0.21 (0.17, 0.27)	<0.001	0.41 (0.30, 0.55)	<0.001
Radiation + surgery	0.57 (0.42, 0.76)	<0.001	0.68 (0.50, 0.94)	0.017
Radiation alone	0.45 (0.36, 0.57)	<0.001	0.60 (0.46, 0.78)	0.001
Primary site (IPLC)
Main	Ref		Ref
Upper	0.33 (0.19, 0.60)	<0.001	0.82 (0.37, 1.82)	0.623
Middle	0.43 (0.23, 0.80)	<0.001	1.0 (0.43, 2.34)	0.989
Low	0.28 (0.15, 0.50)	<0.001	0.66 (0.29,1.48)	0.315
Laterality (IPLC)
Left	Ref
Right	1.08 (0.97, 1.43)	0.391
Histology (IPLC)
Small cell carcinoma	Ref
Large cell carcinoma	0.82 (0.46, 1.46)	0.494
Squamous cell carcinoma	1.08 (0.69, 1.69)	0.725
Adenocarcinoma	0.66 (0.43, 1.02)	0.059
Other	0.77 (0.46, 1.29)	0.328
Histology of IPLC and SPLC
Different	Ref		Ref
Same	0.66 (0.53, 0.81)	0.001	1.09 (0.87, 1.38)	0.459
Tumor stage (IPLC)
I	Ref
II	0.81 (0.55, 1.99)	0.291
III	0.85 (0.65, 1.12)	0.258
IV	0.96 (0.53, 1.74)	0.889
Interval time of IPLC and SPLC	1.0 (0.995, 1.004)	0.969
Chemotherapy (IPLC)	Ref
No/unknown
Yes	1.19(0.97,1.43)	0.068
Radiation/surgery(IPLC)
No	Ref
Surgery alone	0.80(0.43,1.50)	0.487
Radiation	0.91(0.46,1.82)	0.794
Radiation + surgery	1.77(0.90,3.43)	0.098

Note. SPLC, second primary lung cancer.